Form 8-K - Current report:
SEC Accession No. 0001628280-25-025573
Filing Date
2025-05-14
Accepted
2025-05-14 17:15:04
Documents
16
Period of Report
2025-05-14
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K abcl-20250514.htm   iXBRL 8-K 25847
2 EX-99.1 a2025-05x14pressrelease.htm EX-99.1 6405
6 a2025-05x14pressrelease001.jpg GRAPHIC 230521
7 a2025-05x14pressrelease002.jpg GRAPHIC 204162
  Complete submission text file 0001628280-25-025573.txt   753008

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT abcl-20250514.xsd EX-101.SCH 1788
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT abcl-20250514_lab.xml EX-101.LAB 20678
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT abcl-20250514_pre.xml EX-101.PRE 11962
19 EXTRACTED XBRL INSTANCE DOCUMENT abcl-20250514_htm.xml XML 2796
Mailing Address 150 W 4TH AVENUE VANCOUVER A1 V5Y 1G6
Business Address 150 W 4TH AVENUE VANCOUVER A1 V5Y 1G6 (604) 559-9005
AbCellera Biologics Inc. (Filer) CIK: 0001703057 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39781 | Film No.: 25947073
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)